Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system and the leading cause of non-traumatic neurological disability in young adults in the United States and Europe. The clinical disease course is variable and starts with reversible episodes of neurological disability in the third or fourth decade of life. Microarray-based comparative gene profiling provides a snapshot of genes underlying a particular condition. Several large scale microarray studies have been conducted using brain tissue from MS patients. In this review, we summarize existing data from different gene expression profiling studies and how they relate to understand the pathogenesis of MS.
Introduction
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS). MS affects more than 2 million people worldwide, making it the leading cause of non-traumatic neurological disability in young adults in North America and Europe (Hauser and Oksenberg, 2006; Noseworthy, 1999; Noseworthy et al., 2000; Trapp and Nave, 2008; Weinshenker, 1998) . The majority (~85%) of MS patients have a biphasic disease course, beginning with the primary phase termed relapsing-remitting MS (RR-MS). During this phase, patients experience alternating episodes of neurological disability and recovery that can last for many years (Hauser and Oksenberg, 2006; Noseworthy, 1999; Noseworthy et al., 2000; Trapp and Nave, 2008) . Within 25 years,~90% of RR-MS patients develop a secondary-progressive disease course (SP-MS), which is characterized by steady neurological decline (Noseworthy et al., 2000; Trapp and Nave, 2008; Weinshenker et al., 1989) . About 10% of MS patients also exhibit a disease course with steady decline in neurological function without recovery and are classified as primary progressive MS (PP-MS). A small minority of MS patients (~5%) suffer from a disease course with progressive neurological decline accompanied by well demarcated acute attacks with or without recovery. This disease course is classified as progressive-relapsing MS (PR-MS).
Since the late 1990s, MS research has refocused on the role of axonal and neuronal pathology, and neurodegeneration is generally accepted as the major cause of irreversible neurological disability in MS patients. Axonal transection and degeneration occur in the setting of acute inflammatory demyelination (Trapp et al., 1998) and as a consequence of chronic demyelination (Bjartmar et al., 2000; Dutta et al., 2006; Ganter et al., 1999; Lovas et al., 2000) . As axon pathology and frequency of transected axons in acute MS lesions correlate with the degree of inflammation (number of immune cells) (Ferguson et 
